Pharmaceutical Companies

Lifecore Biomedical

Country: 🇺🇸United States

Ownership: -

Established: -

Employees: 484

Market Cap: $146.4M

Website: -

Lifecore Biomedical, Inc. engages in the development and manufacturing of pharmaceuticals products and services. It focuses on selling products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans, and non-HA products for medical use primarily in the Ophthalmic, Orthopedic and other markets. The company was...

Lifecore Biomedical

🇺🇸United States

Ownership: -

Established: -

Employees: 484

Market Cap: $146.4M

Website: -

Amylyx Pharmaceuticals

Country: 🇺🇸United States

Ownership: Public

Established: 2014-01-01

Employees: 384

Market Cap: $145M

Website: http://www.amylyx.com

Amylyx Pharmaceuticals

🇺🇸United States

Ownership: Public

Established: 2014-01-01

Employees: 384

Market Cap: $145M

Website: http://www.amylyx.com

aTYR PHARMA INC

Country: 🇺🇸United States

Ownership: Public

Established: 2005-01-01

Employees: 59

Market Cap: $141.7M

Website: http://www.atyrpharma.com

aTYR PHARMA INC

🇺🇸United States

Ownership: Public

Established: 2005-01-01

Employees: 59

Market Cap: $141.7M

Website: http://www.atyrpharma.com

INmune Bio Inc.

Country: 🇺🇸United States

Ownership: -

Established: -

Employees: -

Market Cap: $139.6M

Website: -

INmune Bio Inc.

🇺🇸United States

Ownership: -

Established: -

Employees: -

Market Cap: $139.6M

Website: -

Kodiak Sciences

Country: 🇺🇸United States

Ownership: -

Established: -

Employees: 111

Market Cap: $138.9M

Website: -

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009...

Kodiak Sciences

🇺🇸United States

Ownership: -

Established: -

Employees: 111

Market Cap: $138.9M

Website: -

CervoMed

Country: 🇺🇸United States

Ownership: -

Established: -

Employees: 8

Market Cap: $137.5M

Website: -

CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. The company was founded in1995 and is headquartered in Boston, MA.

CervoMed

🇺🇸United States

Ownership: -

Established: -

Employees: 8

Market Cap: $137.5M

Website: -

Vigil Neuroscience

Country: 🇺🇸United States

Ownership: Public

Established: 2020-01-01

Employees: 69

Market Cap: $137.1M

Website: http://www.vigilneuro.com

Vigil Neuroscience, Inc. engages in the provision of biotechnology research services. Its focus is improving the lives of patients, caregivers, and families affected by neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. The company was founded on June 22, 2020 and is headquartered in Watertown, MA.

Vigil Neuroscience

🇺🇸United States

Ownership: Public

Established: 2020-01-01

Employees: 69

Market Cap: $137.1M

Website: http://www.vigilneuro.com

Adagene AG

Country: 🇨🇭Switzerland

Ownership: -

Established: -

Employees: -

Market Cap: $133.2M

Website: -

Adagene AG

🇨🇭Switzerland

Ownership: -

Established: -

Employees: -

Market Cap: $133.2M

Website: -

ALX Oncology

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 2015-01-01

Employees: 72

Market Cap: $131.1M

Website: http://www.alxoncology.com

ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia in March 2015 and is headquartered...